| Bioactivity | AK106-001616 is a potent and selective inhibitor of cytosolic phospholipase A2 (cPLA2) (IC50=3.8 nmol/L). AK106-001616 is able to reduce the production of prostaglandins (PG) E2 and leukotrienes (LT) B4 by stimulated cells. AK106-001616 can be used in the study of inflammatory diseases, neuropathic pain and pulmonary fibrosis[1]. |
| CAS | 590416-75-4 |
| Formula | C26H25N3O3 |
| Molar Mass | 427.50 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Shimizu, Hirotomo, et al. AK106-001616, a potent and selective inhibitor of cytosolic phospholipase A2: in vivo efficacy for inflammation, neuropathic pain, and pulmonary fibrosis. Journal of Pharmacology and Experimental Therapeutics 369.3 (2019): 511-522. |
AK106-001616
CAS: 590416-75-4 F: C26H25N3O3 W: 427.50
AK106-001616 is a potent and selective inhibitor of cytosolic phospholipase A2 (cPLA2)(IC50=3.8 nmol/L). AK106-001616 is
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.